QLS-111
Primary Open-Angle Glaucoma, Ocular Hypertension
Key Facts
About Qlaris Bio
Qlaris Bio is a private, clinical-stage biotech based in Cambridge, Massachusetts, advancing a novel mechanism for treating glaucoma and ocular hypertension. The company's core innovation targets episcleral venous pressure (EVP) to achieve intraocular pressure reduction beyond current standards of care. With its lead program QLS-111 in clinical development, Qlaris is positioned to address a significant unmet need in a large, chronic market. The company is led by an experienced team with deep ophthalmology and biotech expertise, supported by a strong scientific advisory board anchored by its academic founder.
View full company profileAbout Qlaris Bio
Qlaris Bio is a private, clinical-stage biotech based in Cambridge, Massachusetts, advancing a novel mechanism for treating glaucoma and ocular hypertension. The company's core innovation targets episcleral venous pressure (EVP) to achieve intraocular pressure reduction beyond current standards of care. With its lead program QLS-111 in clinical development, Qlaris is positioned to address a significant unmet need in a large, chronic market. The company is led by an experienced team with deep ophthalmology and biotech expertise, supported by a strong scientific advisory board anchored by its academic founder.
View full company profile